UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 8, 2024

NextCure, Inc.

(Exact name of registrant as specified in its charter)

001-38905

Delaware (State or other jurisdiction of incorporation)

(Commission File Number)

47-5231247 (IRS Employer Identification No.)

20705 (Zip Code)

9000 Virginia Manor Road, Suite 200 Beltsville, Maryland

(Address of principal executive offices)

Registrant's telephone number, including area code: (240) 399-4900

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Derecommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

D Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value per share	NXTC	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company 🗵

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. \Box

Item 7.01 Regulation FD Disclosure

Beginning on November 8, 2024, the Company will be hosting calls with members of the investment community, which may reference presentation materials. The Company is furnishing a copy of such presentation materials, which is attached hereto as Exhibit 99.1.

The information furnished in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of the Exchange Act, or otherwise subject to the liabilities of that section, and is not incorporated by reference into any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.	Description
<u>99.1</u>	<u>NextCure, Inc. Presentation dated November 8, 2024</u>
104	Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 8, 2024

NEXTCURE, INC.

By: <u>/s/ Steven P. Cobourn</u> Name: Steven P. Cobourn Title: Chief Financial Officer **Next**Qure

Corporate Presentation

NASDAQ: NXTC




Forward-Looking Statement

To the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward looking statements under the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations, forecasts assumptions and other information available to NextCure as of the date hereof. Forward-looking statements include statements regardin NextCure's expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as "may, "will," "potential," "expects," "believes," "intends," "hope," "towards," "forward," "later" and similar expressions. Examples of forward-lookin statements in this presentation include, among others, statements about the development plans for our products, statements about the progress and evaluation and expected timing of results of NextCure's ongoing or planned clinical trials, expectations regarding the potentia benefits, activity, effectiveness and safety of our research stage, preclinical stage, and clinical stage therapeutic candidates, NextCure' financial guidance, expected upcoming milestones, and NextCure's plans, objectives and intentions with respect to the discovery an development of therapeutic products. Forward-looking statements involve substantial risks and uncertainties that could cause actual result to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: the impact of the COVID-19 pandemic on NextCure's business, including NextCure's clinical trials, third parties on which NextCure relies and NextCure' operations; positive results in preclinical studies may not be predictive of the results of clinical trials; NextCure's limited operating history and no products approved for commercial sale; NextCure's history of significant losses; NextCure's need to obtain additional financing; risk related to clinical development, marketing approval and commercialization; the unproven approach to the discovery and development c product candidates based on NextCure's discovery platform; and dependence on key personnel. More detailed information on these and additional factors that could affect NextCure's actual results are described in NextCure's filings with the Securities and Exchange Commission (the "SEC"), including in Item 1A of NextCure's most recent Form 10-K, subsequent Form 10-Q and elsewhere in the Company's filings with the SEC. You should not place undue reliance on any forward-looking statements. Forward-looking statements speak only as of the date of this press release, and NextCure assumes no obligation to update any forward-looking statements, except as required by law, even i expectations change.

Next@ure

Value-Driven ADC Opportunity









Endometrial CANCER

LNCB74

LEVERAGING OUR DEEP EXPERTISE IN B7-H4 AND COLLABORATION WITH LCB TO DEVELOP A DIFFERENTIATED THERAPEUTIC

IND 4Q 2024

Focused on a Clinically Validated Target with High Unmet Need

PROGRAMS	TARGET	CELLS	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	ANTICIPATE MILESTONI
LNCB74 (ADC) Co-development with	B7-H4	Tumor Cells	Breast, C Endomet					POC 4Q 2025

NOVEL APPROACH

Unique antibody linker strategy Co-development partnership with LCB

B7-H4 ADC



Differentiated ADC

DEEP EXPERTISE

Significant B7-H4 experience LCB's substantial ADC know-ho

THERAPEUTIC POSITIONII

Improved safety and efficacy

PATIENT SELECTION STRATEGY


CLIA validated IHC biomarker assays



B7-H4 is the Next Target of Interest in Women's Cancer

		Chem [*] join big-league rivals in conjugate race *Currently known as LigaChemBio
Journal of Clinical Oncology*	Phase 1 study of SGN-B7H4V, a novel, investigational vedotin antibody–drug conjugate directed to B7-H4, in patients with advanced solid tumors (SGNB7H4V-001, trial in progress).	ANNALS of ONCOLOGIENT 3810 First-in-human/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors
Journal of Clinical Oncology*	XMT-1660: A phase 1b trial of a B7-H4 targeted antibody drug conjugate (ADC) in breast, endometrial, and ovarian cancers.	ApexOnco OncologyPipeline Pfizer shuffles its deck post-Seagen The group's B7-H4-targeting bispecific is out, in favour of Seagen's ADC
American Associatio for Cancer Research	Abstract 2947: Preclinical evaluation of a novel B7- H4 targeted antibody-drug conjugate AZD8205 as a single agent and in combination with novel PARP inhibitor and checkpoint blockade	FIERCE Biotech In 2nd big deal of the day, GSK inks \$1.4B pacy for Hansoh gynecology cancer asset

Deep Expertise in B7-H4



LNCB74 IND Year-End 2024



COMPLETED


 $\checkmark\,$ Potent pre-clinical activity in vitro and in vivo

- DRF & GLP tox studies favorable safety and tolerability profile
- ✓ Favorable pre-IND feedback from FDA
- ✓ GMP manufacturing

ONGOING


• Planning for IND filing in 4Q 2024 & Ph1 initiation

LNCB74 Is an Anti-B7-H4 MMAE ADC




LNCB74 Uses Differentiating Glucuronidase Linker for Potentially Improved Safety & Efficacy


Next@ure




Key Differentiating Features of Glucuronidase Linkers



LNCB74 Shows Potent Anti-Tumor Activity in CDX and PDX Models



LNCB74 is More Effective than Comparator B7-H4-MMAE



B7-H4 is a Validated ADC Target

Next@ure

		ÖSeagen ZPfizer	Mersana		AstraZeneca	DualǐtyBio) Be ^{陝 思 生 物}
Key Features	LNCB74	SGN-B7H4V	XMT-1660	HS-20089	AZD8205	DB-1312 / BG-0
	• B7-H4 mAb	• B7-H4 mAb	• B7-H4 mAb	• B7-H4 mAb	• B7-H4 mAb	• B7-H4 mAb
	Glucuronidase cleavable linker	Val-Cit cleavable linker	Protease cleavable linker	Protease cleavable linker	 Pegylated Val-Ala cleavable linker 	GGFG cleavable linke
ADC Design	 Monomethyl Auristatin E (MMAE) 	 Monomethyl Auristatin E (MMAE) 	 Auristatin F-HPA (Dolasynthen) 	• TOPO1 inhibitor (Exatecan)	TOPO1 inhibitor (Proprietary)	Non-Pgp substrate pa
	• DAR 4	• DAR ~4	• DAR 6	• DAR 6	• DAR 8	• DAR 6
DLT	Safe and tolerable up to 10 mg/kg*	1.25 (N=1) or 1.5 mg/kg (N=2)	TBD	7.2 mg/kg (N=2)	3.2 mg/kg (N=2)	TBD
Common Aes	No major toxicity observed in NHPs	Neutropenia, Peripheral sensory neuropathy, Nausea, Fatigue, Anemia, Dyspnea, Hypotension, and Pneumonia	TBD	Leukopenia, Neutropenia, Nausea, Anemia, Vomiting, Fatigue, Thrombocytopenia, Increased ALT and AST, Anorexia, and Hyponatremia	Nausea, Neutropenia, Thrombocytopenia, Anemia and WBC decrease	TBD
RESPONSES	• IND 4Q 2024	• TNBC: 1 CR / 8 PR (N=42)* • HR+/HER2- Breast: 5 PR (N=24)* • Ovarian: 2 PR (N=15) • Endometrial: 1 CR (N=16)	TBD	• TNBC: 6 PR (N=16) • Ovarian: 2 PR (N=3)	Ovarian 3 PR (N=7) Breast 3 PR (N=17) Endometrial 3 PR (N=12)	TBD
Data Source	*Cyno tox study	*Pfizer Oncology Innovation Day February 29, 2024		2023	E 2024	

GLP Tox and GMP Manufacturing Complete

	TOX STUDY
Species	Cynomolgus
Dose	4, 7 & 10 mg/kg
Range	Q3W, i.v.
Evaluation	Toxicology profiling, pathology, hematology, immunotoxicology
Findings	Favorable safety and tolerability profile

 Master cell bank generated Process development complete Antibody manufactured Clinical supply ready 	GMP MANUFACTURING
Antibody manufactured	Master cell bank generated
	Process development complete
Clinical supply ready	Antibody manufactured
	Clinical supply ready



Opportunity to Develop Differentiated B7-H4 ADC Therapeutic



Programs Available for Partnering

PROGRAMS	TARGET	CELLS	DISCOVERY	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	
NC410		Extracellular	Ovarian					
Combo	LAIR-2	Matrix	Colorectal (CRC)				
NC525	LAIR-1	Leukemia	Acute Myeloi	d Leukemia				
NC605	S15	Osteoclasts	Osteogenesis Imperfecta					
NC181	APOE4	Microglia & Neurons	Alzheimer's Disease					

SIGNIFICANT OPPORTUNITY

- Antibody-drug conjugate targeting B7-H4
- Breast, endometrial and ovarian cancers
- Differentiated linker for improved safety and increased efficacy

2024-2025 DELIVERABLES

- IND submission expected Q4 2024
- Completed GLP tox study and GMP manufacturing for Ph 1 trial
- POC expected in 2025